Bliss GVS Pharma Appoints Narsimha Kamath as Managing Director

Bliss GVS Pharma Limited has announced the appointment of Mr. Narsimha Shibroor Kamath as Director in the capacity of Managing Director. This decision was approved by the Board of Directors on Decembe...

Bliss GVS Pharma Limited has announced the appointment of Mr. Narsimha Shibroor Kamath as Director in the capacity of Managing Director. This decision was approved by the Board of Directors on December 23, 2025, and is subject to shareholder approval via a postal ballot. The voting period for the postal ballot will commence on December 31, 2025, at 9:00 a.m. IST and conclude on January 29, 2026, at 5:00 p.m. IST. The results of the e-voting will be announced on or before February 02, 2026. Mr. Kamath, who is currently the Promoter and Chief Executive Officer of the company, will serve as Managing Director for a period of three consecutive years. His appointment is considered in the best interest of the company due to his extensive industry experience and leadership. He will also be designated as Managing Director & Chief Executive Officer. The proposed remuneration includes a basic salary of ₹1,25,00,000 per annum, with perquisites and other allowances totaling ₹63,74,800 and ₹61,25,200 respectively, subject to annual increments.

Limitations of AI summaries

AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.

Platforms like Prysm provide stock-level and portfolio-level analysis.

Why is Bliss GVS Pharma Limited in the news today?

Bliss GVS Pharma Limited (BLISSGVS) is in the news due to the appointment of a key leadership position like managing director is generally viewed positively by the market as it signals continuity and strategic direction.

Key Management ChangesBoard ChangesShareholder Meetings
Bliss GVS Pharma LimitedBLISSGVShttps://prysm.fi/v2/analyze/BLISSGVS

AI-Powered Summary

Market Context

Top Queries

More News

Explore Prysm Tools

Related Stories

Bliss GVS Pharma Appoints Narsimha Kamath as Managing Director

December 30, 2025, 11:19 AM

AI Sentiment Analysis

Top Queries to Ask About Bliss GVS Pharma Limited

More Details on This News

Bliss GVS Pharma Limited has announced the appointment of Mr. Narsimha Shibroor Kamath as Director in the capacity of Managing Director. This decision was approved by the Board of Directors on December 23, 2025, and is subject to shareholder approval via a postal ballot.

The voting period for the postal ballot will commence on December 31, 2025, at 9:00 a.m. IST and conclude on January 29, 2026, at 5:00 p.m. IST. The results of the e-voting will be announced on or before February 02, 2026.

Mr. Kamath, who is currently the Promoter and Chief Executive Officer of the company, will serve as Managing Director for a period of three consecutive years. His appointment is considered in the best interest of the company due to his extensive industry experience and leadership. He will also be designated as Managing Director & Chief Executive Officer. The proposed remuneration includes a basic salary of ₹1,25,00,000 per annum, with perquisites and other allowances totaling ₹63,74,800 and ₹61,25,200 respectively, subject to annual increments.

See What Deep Dive Gives You — in Seconds

“what happens when you click Deep Dive “

Instant AI Summary - “Get clean, noise-free earnings breakdowns.”

PDF Insights - “Download detailed, AI-generated reports.”

Metrics Explained -“Key ratios & trends explained in simple language.”

Want to know if this news pushes your stock up or down?

Just tap

deep dive

More News on Bliss GVS Pharma Limited

Discover more trending news on Prysm

View All